Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the month of August 2017. The registrant is an Australian biotechnology company headquartered in Parkville, Victoria. The filing primarily serves to incorporate the company's Corporate Governance Statement for the financial year ended June 30, 2017, into its U.S. registration statements.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a compliance form (Appendix 4G) detailing adherence to the ASX Corporate Governance Council Principles and Recommendations rather than a financial results report.
Material Changes
No material financial changes or operational updates are disclosed in this specific filing. The document confirms that the Corporate Governance Statement is accurate and up to date as of June 30, 2017, and has been approved by the board.
Guidance, Outlook, and Governance Disclosures
The filing details the company's compliance with ASX Corporate Governance Council recommendations for the period ended June 30, 2017. Key governance disclosures include:
- Board Structure: The company has a Nomination Committee and an Audit Committee, both chaired by independent directors. A majority of the board consists of independent directors.
- Executive Leadership: The company does not follow the recommendation that the Chair of the Board be an independent director separate from the CEO; an explanation for this deviation is provided in the Corporate Governance Statement.
- Risk Management: The company does not have a dedicated risk committee but employs specific processes to oversee its risk management framework, which is reviewed annually by the board.
- Internal Audit: The company does not have an internal audit function but employs processes to evaluate and improve risk management and internal controls.
- Remuneration: The company has a Remuneration Committee chaired by an independent director. Policies regarding equity-based remuneration hedging are disclosed.
- Diversity: The company has a diversity policy with measurable objectives for gender diversity, disclosed in the Corporate Governance Statement.
Investor Verification Checklist
- Verify the full Corporate Governance Statement (pages 46-54 of the Annual Report) for details on the deviation regarding the Chair/CEO independence.
- Review the Annual Report for the financial year ended June 30, 2017, to obtain actual financial performance metrics (revenue, cash flow, etc.) not present in this filing.
- Confirm the specific processes used for risk oversight and internal control evaluation in the absence of dedicated committees.
- Check the company website (http://pranabio.com/investors/) for the diversity policy summary and committee charters referenced in the filing.